11.2 kg Average Loss With Tirzepatide vs. 5.7 kg With Semaglutide
SURPASS-2 directly compared three tirzepatide doses with semaglutide 1 mg in adults using metformin for type 2 diabetes. Its primary outcome was HbA1c change at 40 weeks; weight change was a secondary outcome. The result does not compare the current highest semaglutide dose, telehealth programs, or individual treatment suitability.
At week 40, mean HbA1c change was −2.01, −2.24, and −2.30 percentage points with tirzepatide 5 mg, 10 mg, and 15 mg, versus −1.86 with semaglutide 1 mg.
Mean weight change was −7.6 kg, −9.3 kg, and −11.2 kg with tirzepatide 5 mg, 10 mg, and 15 mg, versus −5.7 kg with semaglutide. Nausea, diarrhea, and vomiting were common in both groups. Adverse-event discontinuation occurred in 6.0%, 8.5%, and 8.5% of tirzepatide groups versus 4.1% with semaglutide.
Turn the study result into a better program comparison
A direct medicine comparison can help frame clinician questions, but it cannot choose a program. Compare providers on medication status, clinician access, diabetes-care support, public price terms, follow-up, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 1,879 adults with type 2 diabetes inadequately controlled on metformin monotherapy, with baseline HbA1c from 7.0% to 10.5%
- Follow-up
- 40-week treatment period plus 4-week safety follow-up
- Treatment comparison
- Once-weekly tirzepatide 5 mg, 10 mg, or 15 mg compared with once-weekly semaglutide 1 mg, with background metformin continued
- Study design
- Phase 3, multicountry, randomized, active-controlled, parallel-group trial
A study result is not a personal treatment plan
This study does not determine how diabetes medicines should be managed for an individual, what a provider can prescribe, or what insurance will cover. It compared tirzepatide against semaglutide 1 mg under a defined metformin background and did not compare online providers, pharmacy access, or affordability. Those decisions require a licensed clinician and current prescribing information.
Compare tirzepatide and semaglutide programsWhat this result does not show
- The trial was open-label between products because the devices and titration schemes differed, which could affect subjective outcomes and adverse-event reporting.
- It lasted 40 weeks, and the highest tirzepatide dose had limited time at steady state, so it does not establish long-term efficacy or safety.
- It used semaglutide 1 mg rather than a higher-dose comparator, which the paper identifies as a limitation.
- The findings apply to adults with type 2 diabetes using metformin under the trial's entry criteria, not directly to people without diabetes or outside those criteria.
- The study was funded by Eli Lilly; the peer-reviewed paper and disclosure materials are linked at the end of this article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at New England Journal of Medicine